May 14 |
Immatics reports Q1 results
|
May 14 |
Immatics Announces First Quarter 2024 Financial Results and Business Update
|
Apr 29 |
Immatics N.V.: An Intriguing Developmental Concern
|
Apr 27 |
Immatics: Big Pharma Partners, Intriguing Catalysts Make Buy Case
|
Mar 21 |
Immatics reports FY results
|
Mar 21 |
Immatics Announces Full Year 2023 Financial Results and Corporate Update
|
Mar 15 |
With 52% institutional ownership, Immatics N.V. (NASDAQ:IMTX) is a favorite amongst the big guns
|
Feb 3 |
Immatics' (NASDAQ:IMTX) investors will be pleased with their notable 35% return over the last year
|
Feb 3 |
Immatics: Pioneering TCR Therapies In The Fight Against Cancer
|
Jan 18 |
Immatics prices upsized stock offering to raise $175 million
|